Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Perspectives on the mesenchymal origin of metastatic cancer.

Huysentruyt LC, Seyfried TN.

Cancer Metastasis Rev. 2010 Dec;29(4):695-707. doi: 10.1007/s10555-010-9254-z. Review.

2.

On the origin of cancer metastasis.

Seyfried TN, Huysentruyt LC.

Crit Rev Oncog. 2013;18(1-2):43-73. Review.

3.

Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model.

Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN.

Int J Cancer. 2008 Jul 1;123(1):73-84. doi: 10.1002/ijc.23492.

4.

Snail1-driven plasticity of epithelial and mesenchymal cells sustains cancer malignancy.

Baulida J, García de Herreros A.

Biochim Biophys Acta. 2015 Aug;1856(1):55-61. doi: 10.1016/j.bbcan.2015.05.005. Epub 2015 Jun 4. Review.

PMID:
26050961
5.

Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.

Jeevan DS, Cooper JB, Braun A, Murali R, Jhanwar-Uniyal M.

Anticancer Res. 2016 Feb;36(2):523-32.

PMID:
26851006
6.

Concepts of metastasis in flux: the stromal progression model.

Sleeman JP, Christofori G, Fodde R, Collard JG, Berx G, Decraene C, Rüegg C.

Semin Cancer Biol. 2012 Jun;22(3):174-86. doi: 10.1016/j.semcancer.2012.02.007. Epub 2012 Feb 21. Review.

7.

Involvement of mesenchymal stem cells in cancer progression and metastases.

Chang AI, Schwertschkow AH, Nolta JA, Wu J.

Curr Cancer Drug Targets. 2015;15(2):88-98. Review.

PMID:
25619387
8.

EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells.

Xu MH, Gao X, Luo D, Zhou XD, Xiong W, Liu GX.

PLoS One. 2014 Feb 6;9(2):e87893. doi: 10.1371/journal.pone.0087893. eCollection 2014.

9.

Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?

Schramm HM.

J Cancer. 2014 Jan 15;5(2):125-32. doi: 10.7150/jca.8242. eCollection 2014. Review.

10.

Microenvironmental regulation of epithelial-mesenchymal transitions in cancer.

Gao D, Vahdat LT, Wong S, Chang JC, Mittal V.

Cancer Res. 2012 Oct 1;72(19):4883-9. doi: 10.1158/0008-5472.CAN-12-1223. Epub 2012 Sep 20. Review.

11.

Development of a method to isolate circulating tumor cells using mesenchymal-based capture.

Bitting RL, Boominathan R, Rao C, Kemeny G, Foulk B, Garcia-Blanco MA, Connelly M, Armstrong AJ.

Methods. 2013 Dec 1;64(2):129-36. doi: 10.1016/j.ymeth.2013.06.034. Epub 2013 Jul 9.

12.

Clinical significance of epithelial-mesenchymal transition and cancer stem cells.

Topcul M, Cetin I.

J BUON. 2016 Mar-Apr;21(2):312-9. Review.

PMID:
27273939
13.

Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step.

Chui MH.

Int J Cancer. 2013 Apr 1;132(7):1487-95. doi: 10.1002/ijc.27745. Epub 2012 Sep 28. Review.

14.

Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-β.

Mele V, Muraro MG, Calabrese D, Pfaff D, Amatruda N, Amicarella F, Kvinlaug B, Bocelli-Tyndall C, Martin I, Resink TJ, Heberer M, Oertli D, Terracciano L, Spagnoli GC, Iezzi G.

Int J Cancer. 2014 Jun 1;134(11):2583-94. doi: 10.1002/ijc.28598. Epub 2014 Jan 30.

15.

Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors.

Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA.

BMC Cancer. 2012 Jan 24;12:35. doi: 10.1186/1471-2407-12-35.

16.

[The role of TGF-β-related signal transduction pathways in pathogenesis of epithelial-mesenchymal transition as a key element in cancer development and progression].

Pieniążek M, Donizy P, Ziętek M, Szynglarewicz B, Matkowski R.

Postepy Hig Med Dosw (Online). 2012 Sep 7;66:583-91. Review. Polish.

17.

Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells.

Celià-Terrassa T, Meca-Cortés O, Mateo F, Martínez de Paz A, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano JJ, Estarás C, Ulloa C, Álvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernández PL, Thomson TM.

J Clin Invest. 2012 May;122(5):1849-68. doi: 10.1172/JCI59218. Epub 2012 Apr 16.

18.

New insights of epithelial-mesenchymal transition in cancer metastasis.

Wu Y, Zhou BP.

Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):643-50. Review.

19.

E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas.

Wells A, Yates C, Shepard CR.

Clin Exp Metastasis. 2008;25(6):621-8. doi: 10.1007/s10585-008-9167-1. Epub 2008 Jul 4. Review.

20.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J.

Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25.

Supplemental Content

Support Center